Fig. 3.
Early-life FGF2 alters the levels of H3K9me3 in various brain regions of bLR rats. Immunoblot (A) and graph (B) show a significant (n = 6) decrease in the levels of H3K9me3 in HC and NAcc of bLR rats and increased in the levels of H3K9me3 in amygdala of bHR rats treated with FGF2 compared with vehicle treatment (***P < 0.001, n = 6 per group).